Mr. William Williams reports

BRIACELL ANNOUNCES COMPLETION OF 15:1 SHARE CONSOLIDATION

On Jan. 24, 2025, Briacell Therapeutics Corp. completed a share consolidation of the company's issued and outstanding common shares on the basis of one postconsolidation common share for every 15 preconsolidation common shares. The consolidation is being implemented to ensure that the company continues to comply with the listing requirements of the Nasdaq Capital Market.

The postconsolidation common shares are expected to commence trading on the Toronto Stock Exchange and the Nasdaq at market open on Jan. 29, 2025. The postconsolidation common shares will continue to trade on the TSX under the symbol BCT and on the Nasdaq under the symbol BCTX, under a new Cusip number, 107930208.

As a result of the consolidation, the 44,204,061 common shares of the company that were issued and outstanding prior to the effective date have been reduced to 2,946,940 common shares.

As stated in the company's press release announcing the consolidation dated Jan. 3, 2025, no fractional common shares have been issued in connection with the consolidation. However, the company clarifies that each fractional common share remaining after the consolidation that was less than one-half of a common share has been cancelled and each fractional common share that was at least one-half of a common share has been changed to one whole common share. The exercise or conversion price and the number of common shares issuable under any of the company's outstanding convertible securities has been proportionately adjusted in connection with the consolidation.

The postconsolidated common shares are delivered by the company's transfer agent to shareholders holding book shares/direct registration system advice positions, and their preconsolidated shares become null and void automatically. Shareholders holding physical share certificates are required to deposit a completed letter of transmittal and the physical share certificates for cancellation to receive postconsolidated shares. Letters of transmittal were mailed by the company's transfer agent on the effective date. Registered shareholders may also obtain a copy of the letter of transmittal by visiting the company's SEDAR+ profile. Shareholders who hold their common shares through intermediaries (for example, a broker, bank, trust company investment dealer or other financial institution) and who have questions about the consolidation should contact their intermediaries.

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.